Citius Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 09/30/23 | FY 09/30/22 | FY 09/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $90,000 | $90,000 |
| Research and development | $9.2M | $11.9M | $14.8M | $17.7M | $12.2M |
| Operating expenses | $38.5M | $42.0M | $36.7M | $33.3M | $23.5M |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M |
| Interest expense | $267,782 | — | — | — | $10,839 |
| Pretax income | -$38.7M | -$38.8M | -$32.0M | -$33.1M | -$23.1M |
| Income tax expense | $1.1M | $576,000 | $576,000 | $576,000 | $1,233 |
| Net income | -$39.7M | -$39.4M | -$32.5M | -$33.6M | -$23.1M |
| Balance Sheet | |||||
| Cash and equivalents | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M |
| Current assets | $27.9M | $14.2M | $34.4M | $44.6M | $72.8M |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M |
| Current liabilities | $44.9M | $35.8M | $5.8M | $4.5M | $4.0M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M |
| Stockholders' equity | $67.6M | $70.1M | $90.8M | $102.8M | $132.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M |
| Depreciation and amortization | — | $1,432 | $2,668 | $2,923 | $1,492 |
| Stock-based compensation | $10.8M | $11.8M | $6.6M | $3.9M | $1.5M |
| Capital expenditure | — | $28.4M | — | — | $6,938 |
| Free cash flow | — | -$56.6M | — | — | -$24.3M |
Shares outstanding 27.5M · Free float 95.8%
Annual filing data through FY ended September 30, 2025; float as of July 14, 2026.